← Leaderboards
Sun Yong Jeong
Translational Sciences, Inc.
$3,523,818
Attributed
$7,986,862
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2019–23$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,986,862 · 4
By mechanism
R44$7,650,662 · 3
R41$336,200 · 1
Top collaborators
- Guy L Reed7 shared
- Victor F. Tapson2 shared
Most similar at Translational Sciences, Inc.
Same institution · by research overlap
- Paul H Kussie$1,649,990
- Dong Wang$1,679,573
- Tieqiang Zhao$175,560
Others in their field
Other Emerging Leaders on “Acute”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$51,003,204
- Julie Ake · National Institute Of Allergy And Infectious Diseases$41,692,120
- Xinhua Li · Nano Terra, Inc.$29,991,620
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$29,269,420
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
Research focus
AcuteMonoclonal AntibodiesCessation Of LifeIschemic StrokeNovel TherapeuticsPre-ClinicalPhase I TrialPharmacologyTranslational ResearchHemorrhagePreventClinical TrialsSafetyNonhuman PrimateManufacturing ProcessDoseBlood CoagulationChinese Hamster Ovary CellAlteplaseClinical DataAffinityEffective TherapyBrain HemorrhageDisability
Grant awards (7)
Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke$1,283,035
R44 · FY2023 · HL · contact PI
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial$1,408,690
R44 · FY2022 · HL · contact PI
Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke$1,161,162
R44 · FY2022 · HL · contact PI
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial$1,408,991
R44 · FY2021 · HL · contact PI
HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II$1,067,767
R44 · FY2020 · HL · contact PI
HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II$1,321,017
R44 · FY2019 · HL · contact PI
Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke$336,200
R41 · FY2019 · HL · contact PI